XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 32.31

+1.4%

Nov 26 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Olu Emuleomo who started this subject	3/22/2004 2:03:42 AM
From: aknahow	Read Replies (4) of 17367

Reuters Genentech, Xoma drug trial does not meet endpoint Monday March 22, 1:42 am ET NEW YORK, March 22 (Reuters) - A Phase II trial of Genentech Inc. (NYSE:DNA - News) and XOMA Ltd's (NasdaqNM:XOMA - News) psoriasis drug Raptiva for the treatment of psoriatic arthritis did not show significant benefit, the companies said on Monday. The companies said the drug did not reach statistical significance for the test's primary endpoint which looked for at least a 20 percent improvement in the patient's signs and symptoms of arthritis. It said 28 percent of the trial patients receiving the drug reached the endpoint improvement compared with 19 percent of patients given a placebo. Psoriatic arthritis is an inflammatory disease that affects joints, ligaments tendons and sometimes the spine. It is associated with the skin disease psoriasis and occurs in some psoriasis patients, but they are deemed distinct diseases. Raptiva was approved by the U.S. Food and Drug Administration (News - Websites) last October for treating chronic moderate-to-severe plaque psoriasis in adults. //////////////////////////////////////////////////////////////////////////////////////////////////// sorry, don't think it will impact the stock more than 50 cents.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next